CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.02.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Tassilo L A Wachsmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands. Electronic address: t.l.a.wachsmann@lumc.nl. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive, Multiple Myeloma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions.
Abstract (Originalsprache)
Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B∗07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM. In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands. Electronic address: t.l.a.wachsmann@lumc.nl.
- Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.
Förderung
- EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
Zitieren
APA
Wachsmann, T. L. A., Poortvliet, T., Meeuwsen, M. H., Remst, D. F. G., Toes, M. F., Wouters, A. K., Hagedoorn, R. S., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2025). CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.02.035
Vancouver
Wachsmann TLA, Poortvliet T, Meeuwsen MH, Remst DFG, Toes MF, Wouters AK, et al. CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.02.035
BibTeX
@article{Wachsmann2025,
author = {Wachsmann, Tassilo L A and Poortvliet, Teuntje and Meeuwsen, Miranda H and Remst, Dennis F G and Toes, Marijke F and Wouters, Anne K and Hagedoorn, Renate S and Falkenburg, J H Frederik and Heemskerk, Mirjam H M},
title = {CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.02.035}
}
EUVIMED